The Chinese NDRC proposes new rules to address perceived anti-competitive practices in the pharmaceutical industry

China proposes new rules to address perceived anti-competitive practices n the pharmaceutical industry* On 14 August 2017, the National Development and Reform Commission (“NDRC“) released a draft of the Guidelines on Pricing Conduct by Business Operators for Drugs in Shortage and Active Pharmaceutical Ingredients (“Draft Guidelines“). NDRC is seeking comments on the Draft Guidelines until mid-September. One day later, NDRC made public the full text of its decisions against two local companies for excessive pricing and refusal to supply active pharmaceutical ingredients (see here and here), confirming its determination to use antitrust as a key enforcement tool in the pharmaceutical industry. Background The Draft Guidelines are a set of rules implementing the Anti-Monopoly Law (“AML“)

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Hogan Lovells (Beijing)

Quotation

Adrian Emch, The Chinese NDRC proposes new rules to address perceived anti-competitive practices in the pharmaceutical industry, 14 August 2017, e-Competitions Bulletin August 2017, Art. N° 84660

Visites 231

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues